Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%

A Truist Financial analyst set an $83 price target on Viking Therapeutics (VKTX), implying 188% upside from its June 8 opening price. The clinical-stage company is developing VK2735, a weight-loss drug candidate in phase 3 trials, with potential to capture a $150 billion obesity drug market by 2035. However, significant risks exist as the company has no revenue, reported a $359 million net loss in 2025, and faces trial execution risks.